StockData
NRX Pharmaceuticals, Inc. logo

NRX Pharmaceuticals, Inc. (NRXP) stock

NRXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$2.80+0.35 (+14.29%)

Close on Nov 18, 2026Market cap $121.23MP/E –Yield –

NRX Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

NRX Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$19.77M. For fiscal 2025 it was -$14.11M. The highest annual figure on record is -$473.19K in fiscal 2018.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$14.11M–
FY2024Dec 31, 2024-$10.64M–
FY2023Dec 31, 2023-$21.66M–
FY2022Dec 31, 2022-$39.76M–
FY2021Dec 31, 2021-$37.70M–
FY2020Dec 31, 2020-$2.27M–
FY2019Dec 31, 2019-$792.73K–
FY2018Dec 31, 2018-$473.19K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$8.88M–
Q1 FY2026Mar 31, 2026-$4.30M–
Q4 FY2025Dec 31, 2025-$3.71M–
Q3 FY2025Sep 30, 2025-$2.89M–
Q2 FY2025Jun 30, 2025-$4.03M–
Q1 FY2025Mar 31, 2025-$3.48M–
Q4 FY2024Dec 31, 2024-$2.10M–
Q3 FY2024Sep 30, 2024-$2.31M–
Q2 FY2024Jun 30, 2024-$2.56M–
Q1 FY2024Mar 31, 2024-$3.67M–
Q4 FY2023Dec 31, 2023-$3.19M–
Q3 FY2023Sep 30, 2023-$4.56M–
Q2 FY2023Jun 30, 2023-$7.81M–
Q1 FY2023Mar 31, 2023-$6.09M–
Q4 FY2022Dec 31, 2022-$8.32M–
Q3 FY2022Sep 30, 2022-$6.27M–
Q2 FY2022Jun 30, 2022-$14.79M–
Q1 FY2022Mar 31, 2022-$10.38M–
Q4 FY2021Dec 31, 2021-$11.28M–
Q3 FY2021Sep 30, 2021-$12.01M–
Q2 FY2021Jun 30, 2021-$11.39M–
Q1 FY2021Mar 31, 2021-$3.02M–
Q4 FY2020Dec 31, 2020-$406.71K–
Q3 FY2020Sep 30, 2020-$1.13M–
Q2 FY2020Jun 30, 2020-$651.84K–
Q1 FY2020Mar 31, 2020-$76.43K–
Q4 FY2019Dec 31, 2019-$262.07K–
Q3 FY2019Sep 30, 2019-$52.31K–
Q2 FY2019Jun 30, 2019-$180.65K–
Q1 FY2019Mar 31, 2019-$297.70K–
Q4 FY2018Dec 31, 2018-$70.88K–
Q3 FY2018Sep 30, 2018-$67.40K–
Q2 FY2018Jun 30, 2018-$137.08K–
Q1 FY2018Mar 31, 2018-$197.82K–
Q4 FY2017Dec 31, 2017-$135.81K–

More NRX Pharmaceuticals figures

See a number that looks wrong?